TSLP and breast cancer: TSLP secretion by cancer‐associated fibroblasts (CAFs) or tumour cells promotes predominantly Th2‐type inflammation in the tumour microenvironment, mostly via DC activation, thereby leading to worse prognosis in pancreatic cancer, breast cancer, gastric cancer and oropharyngeal squamous cell carcinoma.